Drug complex for treatment of metastatic prostate cancer

a prostate cancer and drug complex technology, applied in the direction of drug compositions, antibody medical ingredients, peptide/protein ingredients, etc., can solve the problem of limited number of treatments available, and achieve the effect of lowering toxicity and high efficacy

Inactive Publication Date: 2005-10-20
BETH ISRAEL DEACONESS MEDICAL CENT INC +2
View PDF9 Cites 41 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008] Combining a targeting carrier molecule with specificity for prostate tissue, bone or both with a cytotoxic drug, which are joined by a lin...

Problems solved by technology

Presently, only a limited number of treatmen...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug complex for treatment of metastatic prostate cancer
  • Drug complex for treatment of metastatic prostate cancer
  • Drug complex for treatment of metastatic prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

In Vitro Testing of Drug Complexes

[0034] PC3 and DU-145 androgen-independent human prostate cancer cell lines obtained from the American Tissue Culture Collection (ATCC) are used for in vitro studies. Cells are grown as monolayer cultures in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine and antibiotics. Radiation survival curves and radiation-induced apoptotic DNA fragmentation patterns in these cell lines are already established in the laboratory. Cells are treated with this drug, carrier-peptide, or carrier-peptide-drug complex with or without radiation. After 24 hours, the cells are trypsinized and plated for clonogenic survival studies. Apoptotic response to the treatments is determined by: 1) agarose gel electrophoresis analysis of DNA fragmentation at 48 and 72 hours after treatment, 2) morphological observations after staining with DAPI, and 3) terminal deoxytransferase-mediated dUTP Nick End Labeling (TUNEL) assay.

example 2

In Vivo Testing of Drug Complexes

[0035] Two human prostate carcinoma tumor lines grown as xenografts in male SCID mice are used: the human DU-145 prostate carcinoma which is not androgen dependent and the human LNCaP prostate carcinoma which produces PSA and has a well characterized androgen receptor and response to androgens. The drug complexes are administered up to maximally tolerated doses alone and in conjunction with fractionated radiation therapy (137Cs Gamma Cell 40) delivered to the tumor bearing limb.

[0036] The progress of each tumor is assessed thrice weekly by caliper measurements until the tumors reach 2000 mm3. Tumor growth delay is calculated as the number of days for each tumor to reach a volume of 500 mm3 as compared to untreated controls. The efficacy of combination treatments is assessed using isobologram analysis for determination of additivity / synergy. [0037] PHASE I CLINICAL TRIAL: (MAXIMAL TOLERABLE DOSE ASSESSMENT)

[0038] Based on the results of the in vitr...

example 3

Effect of Thapsigargin (TG) on Cell Proliferation In Vitro

[0039] Preliminary in vitro data indicate that TG inhibits cell proliferation (Table 1, DU 145 cells) and clonogenic cell survival (Table 2, PC3 cells) of androgen independent human prostate cancer cells.

[0040] Table 1 shows the effect of thapsigargin and radiotherapy on proliferation of DU-145 prostate cancer cells. The results indicate that thapsigargin inhibits cell proliferation vitro.

TABLE 1Effect of TG and RT on proliferation of DU-145 prostate cancer cells*ThapsigarginTotal Number of Cells per Dish (106)(nM)0 Gy2 Gy4 Gy8 Gy02.11.41.20.5201.00.80.30.41000.70.50.50.44000.70.40.30.3

*Cells were irradiated 2 hours after adding TG or DMSO. At 48 hours cells were trypsinized and counted after staining with trypan blue. <5% of the cells were trypan blue + at that time.

[0041] Table 2 shows the effect of thapsigargin and radiotherapy on clonogenic cell survival of PC3 prostate cancer cells. The results indicate that thapsig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Login to view more

Abstract

A drug complex for delivery of a drug or other agent to a target cell, comprising a targeting carrier molecule which is selectively distributed to a specific cell type or tissue containing the specific cell type; a linker which is acted upon by a molecule which is present at an effective concentration in the environs of the specific cell type; and a drug or an agent to be delivered to the specific cell type. In particular, a drug complex for delivering a cytotoxic drug to prostate cancer cells, comprising a targeting carrier molecule which is selectively delivered to prostate tissue, bone or both; a peptide which is a substrate for prostate specific antigen; and a cytotoxic drug which is toxic to androgen independent prostate cancer cells.

Description

RELATED APPLICATION [0001] This application is a divisional application of U.S. application Ser. No. 10 / 119,417 filed Apr. 9, 2002, which is a divisional application of U.S. application Ser. No. 09 / 110,822 filed Jul. 6, 1998 (now U.S. Pat. No. 6,368,598), which is a continuation-in-part of application Ser. No. 09 / 003,838 filed Jan. 7, 1998, now abandoned, which is a continuation of application Ser. No. 08 / 713,114 filed Sep. 16, 1996, now abandoned. The entire teachings of these applications are incorporated herein by reference.BACKGROUND OF THE INVENTION [0002] Prostate cancer is the second most common malignancy in men and is the third most common cause of cancer death in men older than age 55. Harrison's Principles of Internal Medicine, Eds. J. D. Wilson et al., 11th Edition, pp. 1630-1633, McGraw Hill, New York, 1991. New methods of identifying and treating prostate cancer early are extremely important in saving the lives of those afflicted. Presently, only a limited number of tr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/06A61K38/08A61K38/14A61K38/16A61K39/395A61K47/48A61P35/04
CPCA61K38/06A61K47/48338A61K47/48046A61K38/08A61K47/65A61K47/543A61P35/04
Inventor D'AMICO, ANTHONYBUBLEY, GLENNJEBARATNAM, DAVIDWEINBERG, JAMES
Owner BETH ISRAEL DEACONESS MEDICAL CENT INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap